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Quinolones are a family of antimicrobial agents that have been used in antibacterial and anticancer chemotherapy. Fluo-
roquinolone targets DNA gyrase and topoisomerase IV enzymes affecting several cellular processes, like cell death and pro-
liferation; the best way to act is in the form of carboxylic acid or, recently, as quinolone-metal complex. In this work, the use of
boron is shown as an alternative of metal to form a complex by incorporating to fluoroquinolone as an electron withdrawing
substituent to activate the C-7 position chemoselectively for the production of new fluoroquinolone hybrids and test their effects
on cell proliferation. Fluoroquinolone-boron complexes were synthesized according to the Gould–Jacobs cyclization method, and
five hybrid fluoroquinolone-boron compounds were obtained by SNAr reaction, yielding 31 to 46%, at 80°C, and in 10 to 25 hours
of reaction. .e effect of the five fluoroquinolone-boron hybrids was evaluated in cervical cancer cell lines by cell proliferation
assay. 7-hydantoin-fluoroquinolone-boron and 7-dihydropyridine-fluoroquinolone-boron complexes showed the strongest effect
according to dose-response assay, respectively. .e fluoroquinolone-boron hybrid complex showed proliferation inhibition in
SiHa and CasKi cells, opening the possibility to use them as potential agents for the treatment of cancer.
1. Introduction
.e antibacterial quinolones are synthetic compounds based
on 4-oxo-1,4-dihydroquinoline-3-carboxylic acid skeleton
and are used in the treatment of infectious diseases [1]..ese
quinolones have target as DNA gyrase and topoisomerase
IV enzymes [2]. Recently, some studies showed that the
family of quinolone antibiotics is promising drugs for the
treatment of some cancer diseases [3]. Cervical cancer is one
of the most frequent diseases in the world and the second
type of cancer that kills most women worldwide, with an
estimated global incidence of 470,000 new cases and over
200,000 deaths per year [4]. Cancer treatment is based on
radiotherapy and chemotherapy; however, in more than 50
% of the cases, resistance is presented [5]. .erefore, new
drugs are important to improve or complement treatments.
Several quinolones modifications have been shown to im-
prove properties in cancer treatment. Some modifications
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comprise ß-keto and carboxylic acid moiety that are re-
quired for hydrogen-bonding interactions with DNA gyr-
ases or/and DNA bases, and therefore, both two functional
group moieties are essential [6]. .e proximity of the car-
boxyl and keto groups on the fluoroquinolone molecule
would account for good chelating properties [7], suggesting
that the interaction of the quinolone complexed to metal is a
major step [8].
Metal quinolone chelates play an important role in drug
bioavailability, and decreased absorption is produced when it
is coadministered with magnesium-aluminum antacids [9] or
cations like calcium, iron, or zinc present in multivitamins
food [10]. Studies of fluoroquinolone complexed with copper
(II), iron, palladium, platinum, and bismuth were found to
have higher antibacterial activity than uncomplexed quino-
lones [11–14]. From these studies, ruthenium, gold, and silver
have shown to be interesting molecules for cancer and an-
tiviral therapies [15–17]. Fluoroquinolone metal complex also
improved physicochemical properties in quinolones, such as
more solubility, pharmacokinetic property and bioavailability
[18]. Cervical cancer treatment generally overrides the drugs
used; therefore, new compounds with cell proliferation in-
hibition potential are imperative. Different cellular processes
like migration, invasion, apoptosis, and proliferation are
altered by complex quinolones. Fluoroquinolone inhibits
migration and invasion in colon and breast cancer cell lines
[19, 20]. It has been proved that metal incorporation in
fluoroquinolone induces HeLa cell death [21]. Interestingly,
benzothiazol ring substitution potentialized proliferation
inhibition [3]. Synthesis of fluoroquinolone with new mod-
ifications represents an opportunity to find new compounds
that could be used in cancer treatment.
In this paper, the use of boron is shown as an alternative to
form a complex with metal that is incorporated to fluo-
roquinolone as electron withdrawing substituent to activate the
C-7 position chemoselectively [22–25]. .ere is no paper
reporting the use of fluoroquinolone-boron complexes as
antimicrobial or anticancer agents. In the present work, flu-
oroquinolones were used for the production of new fluo-
roquinolone hybrids which are proposed here as potential
anticancer agents according to theoretical and physicochemical
properties and antiproliferative effect [26, 27]. .eir effects
were proved on SiHa and CasKi cervical cancer cell lines. .e
five new compounds synthesized herein were evaluated to
prove their cell proliferation inhibition capability by dose-
response assays, showing dependent and differential effect
between them. .e most prominent effect on cell proliferation
inhibition was reached sequentially with hydantoin-, dihy-
dropyridine-, carbazole-, and benzimidazole-fluoroquinolone
complex treatment. Conversely, fluoroquinolone-uracil com-
plex did not show any effect. .ese new compounds represent
an alternative to cancer drug treatments.
2. Materials and Methods
2.1. Instruments. .e melting points were obtained with
an Electrothermal, IA 9000 melting point apparatus model.
.e IR spectra were recorded on a Nicolet iS10 FT-IT
(.ermo-Scientific) spectrometer with Smart iTR-ATR
diamond. .e NMR spectra were obtained on a Varian
Mercury 400MHz spectrometer using TMS as an internal
standard.
2.2. Synthesis. Fluoroquinolone-boron complex 2 was
synthesized according to Leyva et al. method [24].
332.85 μmol of the fluoroquinolone 2 and 0.5mmol of
the heterocycle (3,5-diethoxycarbonyl-2,6-dimethyl-1,4-
dihydropyridine, uracil, 5,5-diphenylhydantoine, benzimi
dazoleor1,2,3,4-tetrahydrocarbazole) were added in 1.5mL
of DMSO (for 3a–d, f ) or CH3CN (for 3e) and 69.4 μL of
TEA solution..eir action mixture was stirred and heated at
80°C and monitored with thin layer chromatography until
reaction was completed. .en, 1mL of ethanol was added to
obtain a solid, which was filtered, washed with cold ethanol,
and recrystallized with CH3CN.
Difluoroboryl 1-ethyl-7-(3,5-diethoxycarbonyl-2,6-dimethyl-
1,4-dihydropyridin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3a). Reaction time (10h), yellow pale solid with an
mp of 300-301°C and 31% yield. FTIR-ATR (cm−1): 3066 (C-H,
aromatic), 1716 (C�O, ketone, ester), 1617 y 1485 (C�C, Ar),
1561 (C�C, vinyl), 1448 (CH3, bend), 1360 (C-N, Ar), 1288,
1230 (C-O, ester), 1093, 1041 (C-F, Ar). RMN de 1H NMR δ
(DMSO-d6, ppm): 9.09 (s, 1H), 8.52 (s, 1H), 8.26 (d, JH-F ortho
� 10.47Hz, 1H), 7.41 (s, 6H), 4.34 (q, J� 7.30Hz, 4H), 4.10 (q,




time (15–17h), white solid with an mp of 307-308°C and 46%
yield. FTIR-ATR (cm−1): 3066 (C-H, aromatic), 1717 (C�O,
ketone and amide), 1697 (C�O, ketone), 1618 y 1486 (C�C,
Ar), 1559 (C�C, vinyl), 1453 (CH3, bend), 1361 (C-N, Ar),
1289, 1231 (C-O, ester), 1094, 1042 (C-F, Ar). 1H NMR δ
(DMSO-d6, ppm): 9.09 (s, 1H), 8.47 (d, JH-F meta� 5.84Hz, 1H),
8.26 (d, JH-F orto� 9.80Hz, 1H), 7.48 (d, JNH-H� 3.96Hz, 1H),
7.40 (t, J� 7.06Hz, 6H), 7.30 (d, J� 7.06Hz, 4H), 4.58 (q,
J� 7.12Hz, 2H), 1.41 (t, J� 7.12Hz, 3H).
Difluoroboryl 1-ethyl-6-fluoro-4-oxo-7-uracil-1,4-dihy-
droquinoline-3-carboxylate (3c). Reaction time (20 h), white
solid with an mp of 317–319°C and 46% yield. FTIR-ATR
(cm−1): 3062 (C-H, aromatic), 1697 (C�O, ketone, ester, and
amide), 1614 y 1479 (C�C, Ar), 1558 (C�C, vinyl), 1347 (C-
N, Ar), 1387, 1287 (C-O, ester), 1090, 1041 (C-F, Ar).1H
NMR δ (DMSO-d6, ppm): 9.13 (s, 1H), 8.47 (d, JH-F meta
� 6.08Hz, 1H), 8.23 (d, JH-F orto � 9.80Hz, 1H), 7.88 (d,
Jcis � 7.84Hz, 1H), 5.86 (d, Jcis � 7.84Hz, 1H), 4.61 (s, 1H),
4.58 (q, J� 7.00Hz, 2H), 1.43 (t, J� 7.00Hz, 3H). 13 C NMR δ
(DMSO-d6, ppm): 176.46 (C�O), 163.70 (C�O, amide),
156.34 (C�O), 154.03 (vinyl), 149.88 (C�O, amide), 144.99
(Ar), 142.55 (vinyl, uracil), 135.97 (Ar), 126.47 (Ar), 124.36
(Ar), 120.81 (Ar), 116.08 (vinyl), 107.11 (Ar), 102.25 (vinyl,
uracil), 49.61 (CH2), 14.64 (CH3).
Difluoroboryl 1-ethyl-7-(1,2,3,4-tetrahydrocarbazol-5-yl)-
6-fluoro-4-oxo-1,4-dihydroquinolin-3-carboxylate (3d). Reac-
tion time (20–25 h), yellow pale solid with an mp of 293–
300°C and 46% yield. FTIR-ATR (cm−1): 3066 (C-H, Ar),
2993 (C-H, Aliph), 1717 (C�O, ketone), 1618, 1504, 1486,
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(C�C, Ar), 1562 (C�C, vinyl), 1451 (CH3, bend), 1361, 1306 (C-
N,Ar), 1289, 1230 (C-O, ester), 1093, 1021 (C-F, Ar). 1HNMR δ
(DMSO-d6, ppm): 8.94 (s, 1H), 8.14 (d, JH-F orto� 8.95Hz, 1H),
7.87 (d, JH-F meta� 5.75Hz, 1H), 7.80 (d, J� 7.05Hz, 1H), 7.44
(d, J� 7.05Hz, 1H), 7.18 (m, 2H), 4.59 (q, J� 7.12Hz, 2H), 2.77




time (10–15 h), white solid with anmp of 316–318°C and 39%
yield. FTIR-ATR (cm−1): 3150, 3063, 3037 (C-H, Ar), 2983
(C-H, Aliph), 1705 (C�O, ketone), 1639 (C�O, ester), 1581,
1498, 1476 (C�C, Ar), 1541 (C�C, vinyl), 1450 (CH3, bend),
1360, 1320 (C-N, Ar), 1135 (C-O, ester), 1035 (C-F, Ar). 1H
NMR δ (DMSO-d6, ppm): 9.08 (s, 1H), 8.65 (s, 1H), 8.54 (d,
JH-Fmeta � 6.12Hz, 1H), 8.38 (d, JH-F orto � 10.16Hz, 1H), 7.54
(m, 1H), 7. 84 (m, 1H), 7.38 (m, 2H), 4.65 (q, J� 7.10Hz,
2H), 1.44 (t, J� 7.10Hz, 3H).
2.3. Cell Lines. .e HPV-16 positive cervical tumor lines
SiHa and CasKi were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Invitrogen Corporation, Carlsbad CA)
enriched with 5% fetal bovine serum (FBS). .e cell lines
were kindly provided by Ph.D. Gariglio’s Lab from CIN-
VESTAV-IPN.
2.4. Cell Proliferation Assay. .e cells were harvested, and
5×104 cells were seeded and incubated for 24 hours before
treated with the five new compounds at different concen-
trations and incubated for 72 hours..e cells were harvested
and countered in a hemocytometer in triplicate. Floating and
adherent cells were collected and included in the counting
analysis. Data were subjected to a two-tailed Student’s t-test.
P< 0.05 was considered statistically significant.
3. Results and Discussion
A general procedure for the synthesis of difluoroboryl 1-
ethyl-6,7-difluoro-1,4-dihydroquinoline-3-carboxylate 2 is
presented as a Gould–Jacobs cyclization process, starting
from 2,3-difluoroaniline 1, followed by N-alkylation and
ester group moiety transformation into boron complex
fluoroquinolone 2, obtaining a molecule with high regio-
selectivity in C-7 position (Figure 1) [24].
With the use of fluoroquinolone-boron complex 2, the
SNAr reaction by addition-elimination was possible for five
heterocycles that presents a weak or reduced nucleophilic
character and stearic high bulk. .e combination of DMSO
and TEA, allowed completed reaction at different times,
such as 3a (10 h), 3b (17 h), 3c (20 h), and 3d (25 h), having
yields between 31 and 46%. In the particular case of 3e, it was
necessary to replace DMSO for CH3CN to obtain 31% yield
in 15 h.
Incorporation of 1,4-dihydropyridine heterocycle into
fluoroquinolone-boron complex 2 achieved a broad band at
1715 cm−1, because the number of C�O vibrations of ketone
groups increased in 3a and uracil moiety in 3c at 1697 cm−1,
but in 3b, hydantoin cycle bonded decreased the intensity of
C�O vibration observed at 1717 cm−1. In the other hand, the
C�C aromatic and alkene group were observed at 1616,
1504, and 1561 cm−1, for 3a; in case of 3e, these numbers of
vibrations were increased and observed at 1638, 1581, 1541,
and 1497 cm−1. Another remarkable vibration was aliphatic
C-H in 3d compound that was appreciated due to the tet-
rahydrocarbazole moiety, while in 3a–c, e, vibrations of C-H
aromatic were observed.
.e five compounds 3a–e were also confirmed for 1H
NMR, where protons in C-6 and C-8 showed two double
signals in the aromatic region, with couple constants of
hydrogen and fluorine atoms in ortho and meta positions,
vinyl hydrogen at 9.09 ppm (C-3) and ethyl group at 4.58
and 1.41 ppm (N-1); therefore, additional signals were from
heterocycles bonded, where 3a shows a singlet at 3.10 ppm
that corresponds to C-4 of pyridine with integration of 2
hydrogens, methyl groups at C-2 and C-6 were observed in
7.41 ppm, as well as the hydrogen for diester group: a quartet
at 4.34 ppm and triplet signal at 1.91 ppm.
3b compound was confirmed with a singlet at 7.48 ppm,
corresponding to secondary amine, whereas in the aromatic
region, a triplet signal at 7.40 ppm and a doublet signal at
7.30 ppm were observed, which belong to diphenyl moiety.
On the other hand, 3c shows a singlet signal from NH
at 4.61 ppm and two doublets for hydrogens of the vinyl
group at 5.86 and 7.86 ppm with couple constant of
Jcis � 7.84Hz. In 3d, two double signals at 7.80 and 7.44 ppm
and a multiple signal at 7.18 ppm were shown, which cor-
respond to benzene moiety of carbazole while 2.77, 2.48
(triplets signal), and 1.69 ppm (multiple signal) for the
moiety saturate carbazole. 3e showed a single signal at
8.65 ppm belonging to hydrogen on C-2 of imidazole and
three multiples signals at 7.54, 7.84, and 7.38 ppm, corre-
sponding to benzene fused to imidazole.
.e subsequent hydrolysis of 3a–e to generate the in-
corporation of carboxylic acid into the quinolone hybrid
drastically changed the molecule polarity, limiting its sol-
ubility and restraining biological assay performance. .is
fact confirms that the quinolone-boron complex helps to
increase the solubility of the fluoroquinolones.
.e 3a–e compounds were tested on cervical cancer cell
lines at different concentrations for 72 h taken in consid-
eration that every 36 h, the cells duplicate their population
giving opportunity to obtain at least four cells for each cell.
.e cervical cancer cell lines SiHa and CasKi were treated
with the 5 compounds synthetized at the indicated doses,
and proliferation was analyzed. 3b and 3a treatment presents
the most prominent effect on SiHa and CasKi cell pro-
liferation (Figure 2(a) and 2(b)). However, it should be noted
that SiHa cell proliferation inhibition is more potent than in
CasKi cells.
In the same sense, 3d and 3e compounds showed a
differential effect between SiHa and CasKi cell proliferation
inhibition, the former beingmore potent. Remarkably, 3d and
3e treatment shows a gradual decrease in SiHa cells, whereas
abrupt change in CasKi cells was achieved with 0.5 and
0.75mM. Interestingly, treatment with 3c did not show the
same effect on SiHa and CasKi cell proliferation but a similar
trend in all the doses used, suggesting an independent effect
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(b)
Figure 2: SiHa and CasKi cells were treated with the ve hybrid uoroquinolones 3a–e at dierent doses. (a) SiHa cells treatment shows a
gradual inhibitory eect with compounds 3a, 3b, 3d, and 3e. (b) CasKi cells treatment shows a gradual eect with 3a while the abrupt eect
was noticed with 3b, 3d, and 3e.
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on SiHa and CasKi cell proliferation. In contrast, the structure
seems not to influence the effect recorded in 3a, 3b, 3d, and
3e. Compounds 3a and 3b have completely different structure
despite sharing similar effect on SiHa and CasKi cell pro-
liferation. Nevertheless, it should be observed that 3d and 3e
demonstrate a significant and promising effect on cancer cell
proliferation inhibition. One of the marks that trigger cancer
development is the reproduction of millions and millions of
cells forming the tumor [28]; therefore, inhibiting this
multiplication is imperative for cervical cancer treatment. It
should be noted that cervical cancer is one of the principal
carcinomas that kill women around the world [4]. One of the
ways that we have to study cancer progression is the use of a
multistep model to have the tool to diagnose on time and
predict the evolution of sickness and to have therapeutic
agents. Our group has proposed a multistep model in cervical
cancer [29] that should be tested with the use of 3a, 3b, 3d,
and 3e. .e incorporation of these compounds to the clinic is
a process that presents different steps before they reach
general population for its application highlighting the po-
tential of 3b, 3a, 3d, and 3e compounds as new alternatives for
cervical treatment.
4. Conclusions
With the use of fluoroquinolone-boron, complex 2 was able
to synthesize the hybrid fluoroquinolone-boron complexes 2
and 3a–c, with yields of 31 to 46%, mild conditions of re-
action, and easy procedure of purification. .e compounds
3a–c have purity and better solubility than fluoroquinolone
with carboxylic acid moiety. 3c compound did not present
effect in SiHa and Caski cell lines in contrast to 3b, 3a, 3d,
and 3e that inhibited cell proliferation in a dose response-
dependent manner, indicating specific effect of these com-
pounds and opening the possibility to use them as potential
agents for the treatment of cancer.
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